文献速递系统性红斑狼疮其他结缔组织病

羟氯喹治疗皮肤型红斑狼疮的多中心双盲随机对照试验

Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
PubMed 文献 · Arthritis Rheumatol · 2017-01-01

这项在日本开展的III期多中心双盲随机平行组试验纳入103例活动性皮肤型红斑狼疮(CLASI活动度评分≥4)患者,按3:1随机接受羟氯喹或安慰剂16周,随后全部接受羟氯喹36周。第16周两组CLASI评分均较基线显著改善但组间无差异,研究者整体评估显示羟氯喹组改善比例更高,其他次要终点支持其疗效,安全性可接受。

要点

  • 第16周羟氯喹组CLASI评分平均变化-4.6(95%CI -6.1,-3.1),安慰剂组-3.2(95%CI -5.1,-1.3),组间P=0.197。
  • 研究者整体评估显示羟氯喹组「改善」和「显著改善」比例51.4%,安慰剂组8.7%(组间P=0.0002)。
  • 羟氯喹相关严重不良事件包括蜂窝织炎、药疹、肝功能障碍和Stevens-Johnson综合征。

核心结论

  • 该随机临床试验结果支持羟氯喹治疗皮肤型红斑狼疮的疗效和耐受性。

研究设计与样本

  • 在日本开展的III期多中心双盲随机平行组临床试验,为基线对照研究,组间差异采用探索性分析。
  • 共纳入103例活动性皮肤型红斑狼疮患者(CLASI活动度评分≥4),按3:1随机接受羟氯喹或安慰剂16周,随后全部患者接受羟氯喹36周单盲期。

主要发现

  • 第16周羟氯喹组CLASI评分平均变化-4.6(95%CI -6.1,-3.1)(P<0.0001),安慰剂组平均变化-3.2(95%CI -5.1,-1.3)(P=0.002),组间差异无统计学意义(P=0.197)。
  • 研究者整体评估显示羟氯喹组「改善」和「显著改善」患者比例51.4%,安慰剂组8.7%(组间P=0.0002)。
  • 其他次要终点支持羟氯喹的疗效。
  • 安全性评估至第55周,羟氯喹相关严重不良事件包括蜂窝织炎、药疹、肝功能障碍和Stevens-Johnson综合征。

关键数值与推荐

  • 主要疗效终点为第16周CLASI活动度评分较基线的下降。
  • 次要终点包括中心照片评估(5分量表)、患者整体评估(7分量表)、Skindex-29评分和研究者整体评估(7分量表,基于其他3个次要终点)。
  • 系统性红斑狼疮患者中评估了疲乏和肌肉骨骼疼痛。

临床怎么用

  • 对于活动性皮肤型红斑狼疮(CLASI活动度评分≥4)患者,羟氯喹治疗可显著改善CLASI评分且耐受性可接受。
  • 研究者整体评估显示羟氯喹组改善比例更高,支持其临床使用。
  • 使用羟氯喹需警惕蜂窝织炎、药疹、肝功能障碍和Stevens-Johnson综合征等严重不良事件。

局限性

  • 主要终点组间差异无统计学意义(P=0.197),组间差异为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and tolerability of hydroxychloroquine (HCQ) in patients with cutaneous lupus erythematosus (CLE), in a phase III clinical trial conducted in Japan. METHODS: We conducted a double-blind, randomized, parallel-group clinical trial. This was a baseline-controlled study, and the group differences were evaluated in an exploratory analysis. A total of 103 patients with active CLE (according to a Cutaneous Lupus Erythematosus Disease Area and Severity Index [CLASI] activity score of ≥4) were included. Patients were randomized 3:1 to receive HCQ or placebo during the 16-week double-blind period, and all patients were given HCQ during the following 36-week single-blind period. The primary efficacy end point was a reduction in the CLASI activity score at week 16. The secondary end points included the central photo evaluation (5-point scale), patient's global assessment (7-point scale), the Skindex-29 score, and investigator's global assessment (7-point scale, based on the other 3 secondary end points). In patients with systemic lupus erythematosus, fatigue and musculoskeletal pain were assessed. Safety was assessed up to week 55. RESULTS: The mean CLASI score at week 16 was significantly improved from baseline in both the HCQ group and the placebo group: mean change -4.6 (95% confidence interval [95% CI] -6.1, -3.1) (P < 0.0001), and mean change -3.2 (95% CI -5.1, -1.3) (P = 0.002), respectively, without between-group difference (P = 0.197). The investigator's global assessment demonstrated a greater proportion of "improved" and "remarkably improved" patients in the HCQ group (51.4% versus 8.7% in the placebo group [P = 0.0002 between groups]). The other secondary end points supported the efficacy of HCQ. Cellulitis, drug eruption, hepatic dysfunction, and Stevens-Johnson syndrome were shown to be serious adverse events related to HCQ use. CONCLUSION: The results of this randomized clinical trial support the efficacy and tolerability of HCQ in patients with CLE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Yokogawa N, Eto H, Tanikawa A, et al. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. Arthritis Rheumatol. 2017. PMID: 27992698. doi:10.1002/art.40018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。